NYSE:HIMS 6 February 2026

Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset

Hims & Hers Health jumped 9.5% to $37.97 by midday after Canaccord Genuity’s Maria Ripps raised her target price to $40 from $32 and left her Buy call unchanged. The new target is about 5% above the current level, after a 25% bump in the target price.

1 July 2026

NYSE:HIMS·Pharmaceutical News·Stock Market

Why Hims & Hers Stock Jumped Today as Its Weight-Loss Bet Gets a Second Look

Hims & Hers Health shares rallied Tuesday, last quoted at $28.98, up about 6.6%, as investors returned to one of the year’s more volatile digital-health trades. The NYSE-listed company traded between $26.05 and $29.17 on volume of about 25 million shares, with a market value near $6.6 billion.

9 June 2026

NYSE:HIMS·Stock Market

Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk

Hims & Hers Health shares dropped ahead of Monday’s open. The telehealth company said it wants to raise $300 million with convertible senior notes, a kind of debt that could switch into cash, equity, or a mix of both.

18 May 2026

NYSE:HIMS·Stock Market

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers Health shares tumbled Tuesday, sliding 14.6% to $24.89 after an intraday dip to $24.29. First-quarter numbers hit, but what really moved the stock was a strategic reset that raised fresh doubts about profits. Growth isn’t the issue, not right now—what’s changed is the appetite to back it unless margins stay intact.

12 May 2026

Growth Stocks·NYSE:HIMS·Stock Market

US Stock Market Today After Hours: S&P 500 Hits Fresh Record as CPI Risk Looms

Stocks in the U.S. hovered just below record territory in after-hours action Monday, with Wall Street leaning on AI-fueled chip gains to offset fresh inflation jitters and stronger oil. Extended trading brought only slight index moves: S&P 500 ticking up 0.02%, Nasdaq 100 adding 0.08%, Dow inching 0.04% higher, StockAnalysis.com data showed.

12 May 2026

NASDAQ:BZFD·NASDAQ:GPRO·NASDAQ:INTC·NASDAQ:QCOM·NYSE:HIMS·Stock Market

Hims & Hers Stock Drops After Surprise Loss as Weight-Loss Pivot Clouds 2026 Outlook

Hims & Hers Health plunged roughly 10% after hours Monday, following a first-quarter revenue miss and an unexpected loss—results that overshadowed its bump in the 2026 sales outlook.

12 May 2026

Earnings Reports·NYSE:HIMS·Stock Market

Hims Stock Faces 15% Earnings Swing as Weight-Loss Pivot Comes Due

Shares of Hims & Hers Health jumped 9.3% to $28.03 on Friday, as options activity suggested traders were bracing for a significant move tied to the company’s first-quarter earnings next week. Pricing on an at-the-money straddle — where both a call and a put at the same strike are purchased — pointed to expectations of a roughly 14.8% swing after results.

8 May 2026

Earnings Reports·NYSE:HIMS·Stock Market

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Shares of Hims & Hers Health surged Thursday after the FDA signaled it would review restrictions on certain peptides—a move that’s opened up a new narrative for investors as the telehealth firm shifts focus from promoting compounded GLP-1 drugs. By early afternoon in New York, the stock was changing hands at $26.65, up $2.36 on the day.

16 April 2026

Health News·NYSE:HIMS·Pharmaceutical Industry·Stock Market

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Shares of Hims & Hers Health surged Wednesday, climbing roughly 14% to $24.29 as of 4:48 p.m. ET and reaching as high as $25.45 earlier in the session. The move followed news that the U.S. Food and Drug Administration plans to reconsider restrictions on several peptides—a development that could open a new growth channel for the telehealth firm.

15 April 2026

Biotechnology·NYSE:HIMS·Stock Market

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health traded flat around $23.82 early Friday in New York, sticking close to Thursday’s finish. All this after a volatile week triggered by news of the telehealth firm’s obesity-drug partnership with Novo Nordisk. The market’s initial relief rally has faded, leaving investors to figure out what kind of earnings this new setup actually delivers.

13 March 2026

NYSE:HIMS·Stock Market

Hims & Hers stock steadies premarket after Novo Nordisk patent suit jolts weight-loss push

Hims & Hers Health stock edged 0.1% higher to $17.25 ahead of the open Wednesday, recovering a sliver after tumbling 10.8% Tuesday and sinking 16% the session before.

11 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares slipped 5.6% to $18.25 on Tuesday. Investors showed caution following Novo Nordisk’s patent suit and ongoing U.S. attention on compounded weight-loss medications.

10 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Shares of Hims & Hers Health tumbled roughly 16%, landing at $19.33 in after-hours trading Monday, after the company scrapped its $49 compounded semaglutide pill and got hit with a patent suit from Novo Nordisk over the weight-loss treatment. Earlier, the stock touched $16.44 before trimming some of those declines.

10 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Early Monday, U.S. stock index futures sent a mixed signal: Dow E-minis climbed 46 points, but S&P 500 and Nasdaq 100 E-minis ticked down. Tech stocks had taken a hit lately, and now the focus is on several upcoming Fed speakers and critical data releases.

9 February 2026

NASDAQ:CRWD·NASDAQ:DDOG·NASDAQ:NVDA·NASDAQ:TEAM·NYSE:HIMS·NYSE:KR·NYSE:NOW·Stock Market·Technology

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly will take the spotlight Monday as Wall Street reopens, after Hims & Hers announced it’s pulling its compounded weight-loss pill in response to a U.S. Food and Drug Administration warning. Lilly's shares closed Friday at $1,058.18, rising 3.7%. “No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said.

8 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk A/S Class B shares could see renewed attention Monday, after Hims & Hers said it's pulling the $49 compounded Wegovy pill, responding to U.S. regulators. Novo’s Copenhagen-listed stock closed out Friday at 295.50 crowns, climbing 5.3%, Reuters data showed.

7 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly and Company finished Friday’s session $37.34 higher, up 3.7% at $1,058.18 a share.

7 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Shares of Hims & Hers Health fell roughly 2.6% to $22.88 Friday afternoon, after ranging from $20.95 to $23.61 earlier in the session. That marks the third straight session in the red, following the company’s move to roll out a $49 compounded alternative to Novo Nordisk’s Wegovy weight-loss pill.

6 February 2026

NYSE:HIMS·Pharmaceuticals

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly and Company shares climbed about 3% on Friday, recovering part of Thursday’s steep 8% drop. The rebound came after the U.S. Food and Drug Administration indicated it would crack down on illegal copycat weight-loss drugs. The stock traded up 3% at $1,051.74. FDA Commissioner Marty Makary emphasized the agency cannot vouch for the “quality, safety or effectiveness” of these non-approved medicines.

6 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

NYSE:HIMS 6 February 2026 - 1 July 2026